Heart failure with preserved ejection fraction

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 14, Issue 6, 2014, Pages s22-s28

  Pellicori, Pierpaolo ^a   Cleland, John GF ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Heart failure; morbidity; mortality; preserved ejection fraction; therapy

Indexed keywords

ATRIAL FIBRILLATION; COMPLICATION; DIABETES MELLITUS; FEMALE; HEART FAILURE; HEART STROKE VOLUME; HUMAN; HYPERTENSION; MALE; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY;

AGED, 80 AND OVER; ATRIAL FIBRILLATION; DIABETES COMPLICATIONS; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; STROKE VOLUME;

EID: 84938198305     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.14-6-s22     Document Type: Article

References (48)

1. Cleland, JG, McDonagh, T, Rigby, AS, et al. National Heart Failure Audit Team for England and Wales. The national heart failure audit for England and Wales 2008–2009. Heart 97 (2011), 876–886 10.1136/hrt.2010.209171.
2. Chen, HH, Lainchbury, JG, Senni, M, et al. Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail 8 (2002), 279–287 10.1054/jcaf.2002.128871.
3. Owan, TE, Hodge, DO, Herges, RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006), 251–259 10.1056/NEJMoa052256.
4. Zile, MR, Gottdiener, JS, Hetzel, SJ, et al. I-PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 124 (2011), 2491–2501 10.1161/CIRCULATIONAHA.110.011031.
5. Mohammed, SF, Mirzoyev, SA, Edwards, WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2 (2014), 113–122 10.1016/j.jchf.2013.11.004.
6. Borlaug, BA, Nishimura, RA, Sorajja, P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 3 (2010), 588–595 10.1161/CIRCHEARTFAILURE.109.930701.
7. Borlaug, BA, Jaber, WA, Ommen, SR, et al. Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. Heart 97 (2011), 964–969 10.1136/hrt.2010.212787.
8. Zile, MR, Baicu, CF, Gaasch, WH, Diastolic heart failure – abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350 (2004), 1953–1959 10.1056/NEJMoa032566.
9. Penicka, M, Bartunek, J, Trakalova, H, et al. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: a pressure-volume loop analysis. J Am Coll Cardiol 55 (2010), 1701–1710 10.1016/j.jacc.2009.11.076.
10. Nikitin, NP, Loh, PH, de Silva, R, et al. Left ventricular morphology, global and longitudinal function in normal older individuals: a cardiac magnetic resonance study. Int J Cardiol 108 (2006), 76–83 10.1016/j.ijcard.2005.04.009.
11. Tan, YT, Wenzelburger, F, Lee, E, et al. The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic -ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol 54 (2009), 36–46 10.1016/j.jacc.2009.03.037.
12. Bhatia, RS, Tu, JV, Lee, DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006), 260–269 10.1056/NEJMoa051530.
13. Lenzen, MJ, Scholte, op, Reimer, WJ, Boersma, E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 25 (2004), 1214–1220 10.1016/j.ehj.2004.06.006.
14. Yusuf, S, Pfeffer, MA, Swedberg, K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003), 777–781 10.1016/S0140-6736(03)14285-7.
15. Cleland, JG, Taylor, J, Freemantle, N, et al. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical -diagnosis of diastolic heart failure: a report from the PEP-CHF study. Eur J Heart Fail 14 (2012), 487–494 10.1093/eurjhf/hfs049.
16. Massie, BM, Carson, PE, McMurray, JJ, et al. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 (2008), 2456–2467 10.1056/NEJMoa0805450.
17. Pitt, B, Pfeffer, MA, Assmann, SF, et al. TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392 10.1056/NEJMoa1313731.
18. Chen, CH, Nakayama, M, Nevo, E, et al. Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol 32 (1998), 1221–1227 10.1016/S0735-1097(98)00374-X.
19. Banerjee, P, Clark, AL, Nikitin, N, Cleland, JG, Diastolic heart failure. Paroxysmal or chronic?. Eur J Heart Fail 6 (2004), 427–431 10.1016/j.ejheart.2004.02.006.
20. Paulus, WJ, Tschˆpe, C, Sanderson, JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 (2007), 2539–2550 10.1093/eurheartj/ehm037.
21. McMurray, JJ, Adamopoulos, S, Anker, SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14 (2012), 803–869 10.1093/eurjhf/hfs033.
22. Yancy, CW, Jessup, M, Bozkurt, B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128 (2013), 1810–1852 10.1161/CIR.0b013e31829e8807.
23. Borlaug, BA, Redfield, MM, Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 123 (2011), 2006–2013 10.1161/CIRCULATIONAHA.110.954388.
24. De Keulenaer, GW, Brutsaert, DL, Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation 123 (2011), 1996–2004 discussion 2005 10.1161/CIRCULATIONAHA.110.981431.
25. Brouwers, FP, de Boer, RA, van der Harst, P, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 34 (2013), 1424–1431 10.1093/eurheartj/eht066.
26. Pellicori, P, Kallvikbacka-Bennett, A, Khaleva, O, et al. Global -longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk -stratification?. Int J Cardiovasc Imaging 30 (2014), 69–79 10.1007/s10554-013-0310-y.
27. Karaahmet, T, Yilmaz, F, Tigen, K, et al. Diagnostic utility of plasma N-terminal pro-B-type natriuretic peptide and C-reactive protein levels in differential diagnosis of pericardial constriction and restrictive cardiomyopathy. Congest Heart Fail 15 (2009), 265–270 10.1111/j.1751-7133.2009.00103.x.
28. Cleland, JG, Pellicori, P, Defining diastolic heart failure and identifying effective therapies. JAMA 309 (2013), 825–826 10.1001/jama.2013.1569.
29. Anand, IS, Rector, TS, Cleland, JG, et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4 (2011), 569–577 10.1161/CIRCHEARTFAILURE.111.962654.
30. Frankenstein, L, Clark, AL, Goode, K, et al. The prognostic value of individual NT-proBNP values in chronic heart failure does not change with advancing age. Heart 95 (2009), 825–829 10.1136/hrt.2008.158626.
31. Pellicori, P, Hutchinson, K, Clark, AL, Cleland, JGF, Does speckle tracking really improve diagnosis and risk stratification in patients with HeFNEF?. J Am Coll Cardiol, 64, 2014, 1535 10.1016/j.jacc.2014.02.616.
32. Pellicori, P, Kallvikbacka-Bennett, A, Zhang, J, et al. Revisiting a -classical clinical sign: jugular venous ultrasound. Int J Cardiol 170 (2014), 364–370 10.1016/j.ijcard.2013.11.015.
33. Pellicori, P, Carubelli, V, Zhang, J, et al. IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging 6 (2013), 16–28 10.1016/j.jcmg.2012.08.012.
34. Yip, GW, Wang, M, Wang, T, et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart 94 (2008), 573–580 10.1136/hrt.2007.117978.
35. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265 (1991), 3255–3264 10.1001/jama.1991.03460240051027.
36. Beckett, NS, Peters, R, Fletcher, AE, et al., HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 (2008), 1887–1898 10.1056/NEJMoa0801369.
37. Setaro, JF, Zaret, BL, Schulman, DS, et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 66 (1990), 981–986 10.1016/0002-9149(90)90937-V.
38. Hung, MJ, Cherng, WJ, Kuo, LT, Wang, CH, Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract 56 (2002), 57–62.
39. Cullington, D, Goode, KM, Zhang, J, et al. Is heart rate important for patients with heart failure in atrial fibrillation?. JACC Heart Fail 2 (2014), 213–220 10.1016/j.jchf.2014.01.005.
40. Ulimoen, SR, Enger, S, Pripp, AH, et al. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J 35 (2014), 517–524 10.1093/eurheartj/eht429.
41. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991), 293–302 10.1056/NEJM199108013250501.
42. Edelmann, F, Wachter, R, Schmidt, AG, et al. Aldo-DHF Investigators. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309 (2013), 781–791 10.1001/jama.2013.905.
43. van Veldhuisen, DJ, Cohen-Solal, A, Bˆhm, M, et al. SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection -fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53 (2009), 2150–2158 10.1016/j.jacc.2009.02.046.
44. Ahmed, A, Rich, MW, Fleg, JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis -investigation group trial. Circulation 114 (2006), 397–403 10.1161/CIRCULATIONAHA.106.628347.
45. Penicka, M, Kocka, V, Herman, D, et al. Cardiac resynchronization therapy for the causal treatment of heart failure with preserved ejection fraction: insight from a pressure-volume loop analysis. Eur J Heart Fail 12 (2010), 634–636 10.1093/eurjhf/hfq068.
46. Chung, ES, Katra, RP, Ghio, S, et al. Cardiac resynchronization therapy may benefit patients with left ventricular ejection fraction >35%: a PROSPECT trial substudy. Eur J Heart Fail 12 (2010), 581–587 10.1093/eurjhf/hfq009.
47. Hutchinson, K, Pellicori, P, Dierckx, R, et al. Remote telemonitoring for patients with heart failure: might monitoring pulmonary artery pressure become routine?. Expert Rev Cardiovasc Ther 12 (2014), 1025–1033 10.1586/14779072.2014.935340.
48. Søndergaard, L, Reddy, V, Kaye, D, et al. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail 16 (2014), 796–801 10.1002/ejhf.111.